Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2013

View Archived Issues

Janssen presents phase III results from QUEST-2 and PROMISE trials of simeprevir

UMC Utrecht Holding divulges new fusion proteins

Shionogi and TB alliance set to collaborate

Allergan advances novel glaucoma compound into preclinical development

Researchers at Variation Biotechnologies patent new vaccines for HCMV infection

First-in-human evaluation of a DNAzyme in adults with nodular basal cell carcinoma

CSL Behring doses first patient in part 3 of global AFFINITY trial program

Researchers from MD Anderson Cancer Center present novel cancer gene therapy

PhaseBio begins first-in-human phase I study of long-acting basal insulin for diabetes

NIH will fund antibacterial resistance research network at Duke University

The Medicines Company enters agreement to acquire ProFibrix

NB Health Laboratory and Mercachem expand partnership

Prolor Biotech begins pivotal phase III trial of hGH-CTP

First-in-human data for vantictumab, an antibody targeting the Wnt pathway

Tunitas Therapeutics receives phase II SBIR grant to advance asthma program

Phase II Pluristem Therapeutics trial to be put on clinical hold

IL-23 receptor modulator peptide shows potential in animal models of arthritis

BTF as a biomarker of severe events in patients with AF

Bayer acquires majority interest in Conceptus

FDA grants fast track designation to NNZ-2566 in Rett syndrome

Almirall patents novel agents for respiratory disorders

The Vanderbilt University discloses new allosteric modulators of the M1 receptor

Novel XIAP inhibitors presented by Bristol-Myers Squibb and Ensemble Therapeutics

Researchers at Allergan design novel FPRL1 ligands

BioMarin commences phase III program for PKU treatment candidate

FDA approves lenalidomide for relapsed/refractory mantle cell lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...